Ventilation Heterogeneity Prior to Lung Resection

Prevalence and Clinical Relevance of Ventilation Heterogeneity and Luminal Cellular Inflammation in Lung Cancer Patients Prior to Lung Resection

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04191174

Enrollment

115

Registered

2019-12-09

Start date

2020-01-06

Completion date

2024-12-01

Last updated

2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

lung cancer, lung resection, ventilation heterogeneity, Technegas V SPECT, hyperpolarized 129Xe MRI, airway inflammation

Brief summary

This is a single centre prospective six-week observational study to understand the prevalence and clinical relevance of abnormal ventilation of the lung (assessed by Technegas ventilation single photon emission computed tomography (V SPECT) and hyperpolarized 129Xe magnetic resonance imaging (MRI)), in the presence or absence of airway inflammation (assessed by sputum cell counts), in lung cancer patients prior to lung resection surgery.

Interventions

OTHERHyperpolarized 129Xe MRI

Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity

OTHERTechnegas V SPECT

Technegas V SPECT to evaluate ventilation heterogeneity

OTHERSputum Induction

Sputum induction to evaluate luminal cellular inflammation

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Undergoing lung resection for lung cancer at St. Joseph's Healthcare (Hamilton, Ontario) in accordance with British Thoracic Society guidelines. * Males and females ≥ 18 years of age. * Able and willing to provide written informed consent. * Able and willing to comply with the study protocol.

Exclusion criteria

* Previous lung resection surgery. * Previous chest radiation. * Patient has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples. * In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia. * Pregnancy.

Design outcomes

Primary

Measure	Time frame	Description
Abnormal ventilation heterogeneity assessed by 129Xe MRI	Baseline	Proportion of patients with abnormal ventilation heterogeneity, assessed by 129Xe MRI, prior to lung resection for lung cancer.
Abnormal ventilation heterogeneity assessed by Technegas V SPECT	Baseline	Proportion of patients with abnormal ventilation heterogeneity, assessed by Technegas V SPECT, prior to lung resection for lung cancer.

Secondary

Measure	Time frame	Description
Technegas V SPECT ventilation heterogeneity and luminal cellular inflammation	Baseline	Proportion of patients with preoperative luminal cellular inflammation in the preoperative ventilation heterogeneity normal and abnormal groups, assessed by Technegas V SPECT.
Incidence of post-operative pulmonary complications (PPC): Technegas V SPECT ventilation heterogeneity	up to 4 weeks	Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity normal and abnormal patients, assessed by Technegas V SPECT
Incidence of PPC: Technegas V SPECT ventilation heterogeneity and luminal cellular inflammation	up to 4 weeks	Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity abnormal patients, assessed by Technegas V SPECT, with and without preoperative luminal cellular inflammation.
Incidence of PPC: 129Xe MRI ventilation heterogeneity and luminal cellular inflammation	up to 4 weeks	Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity abnormal patients, assessed by 129Xe MRI, with and without preoperative luminal cellular inflammation.
Incidence of PPC: 129Xe MRI ventilation heterogeneity	up to 4 weeks	Difference in incidence of PPC and related impact measures in preoperative ventilation heterogeneity normal and abnormal patients, assessed by 129Xe MRI.
129Xe MRI ventilation heterogeneity and luminal cellular inflammation	Baseline	Proportion of patients with preoperative luminal cellular inflammation in the preoperative ventilation heterogeneity normal and abnormal groups, assessed by 129Xe MRI.

Other

Measure	Time frame	Description
Correlation between ventilation heterogeneity quantified by Technegas V SPECT and 129Xe MRI	Baseline	Univariate correlation between preoperative ventilation heterogeneity quantified by Technegas V SPECT and 129Xe MRI.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026